Sarepta Therapeutics (NASDAQ:SRPT) Downgraded by BidaskClub to Hold

BidaskClub downgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a buy rating to a hold rating in a research note issued to investors on Saturday, January 6th.

SRPT has been the subject of several other reports. Goldman Sachs Group restated a buy rating and issued a $71.00 price objective on shares of Sarepta Therapeutics in a report on Friday, October 6th. ValuEngine downgraded shares of Sarepta Therapeutics from a hold rating to a sell rating in a report on Monday, October 2nd. Janney Montgomery Scott started coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 3rd. They issued a buy rating and a $75.00 target price for the company. Oppenheimer reiterated a buy rating on shares of Sarepta Therapeutics in a report on Monday, September 25th. Finally, Robert W. Baird restated a buy rating and set a $101.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, October 17th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and eighteen have issued a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $64.65.

Shares of Sarepta Therapeutics (NASDAQ SRPT) traded down $0.48 on Friday, hitting $65.06. 849,054 shares of the stock were exchanged, compared to its average volume of 1,700,000. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52. The stock has a market capitalization of $4,200.00, a price-to-earnings ratio of -31.89 and a beta of 1.37. Sarepta Therapeutics has a 1 year low of $26.26 and a 1 year high of $68.90.

In related news, SVP Shamim Ruff sold 10,000 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $55.00, for a total value of $550,000.00. Following the completion of the transaction, the senior vice president now directly owns 37,045 shares of the company’s stock, valued at approximately $2,037,475. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Douglas S. Ingram acquired 38,138 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, November 8th. The stock was purchased at an average cost of $52.44 per share, with a total value of $1,999,956.72. Following the completion of the purchase, the chief executive officer now owns 420,196 shares in the company, valued at approximately $22,035,078.24. The disclosure for this purchase can be found here. 9.60% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Sarepta Therapeutics by 4.0% in the 2nd quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock worth $143,572,000 after acquiring an additional 162,543 shares during the last quarter. HealthCor Management L.P. increased its stake in shares of Sarepta Therapeutics by 31.1% in the 2nd quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after acquiring an additional 481,890 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Sarepta Therapeutics by 0.6% in the 4th quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock worth $63,998,000 after acquiring an additional 6,357 shares during the last quarter. Eagle Asset Management Inc. increased its stake in shares of Sarepta Therapeutics by 26.0% in the 3rd quarter. Eagle Asset Management Inc. now owns 1,006,222 shares of the biotechnology company’s stock worth $49,858,000 after acquiring an additional 207,810 shares during the last quarter. Finally, Emerald Advisers Inc. PA increased its stake in shares of Sarepta Therapeutics by 2.1% in the 3rd quarter. Emerald Advisers Inc. PA now owns 893,484 shares of the biotechnology company’s stock worth $40,528,000 after acquiring an additional 18,077 shares during the last quarter. 81.98% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by BBNS and is owned by of BBNS. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/sarepta-therapeutics-srpt-rating-lowered-to-hold-at-bidaskclub/1822184.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August
Mookie Betts Awarded Arbitration of $10.5 Million
Mookie Betts Awarded Arbitration of $10.5 Million


Leave a Reply

 
© 2006-2018 BBNS.